Human VEGF-specific oligonucleotides

Details Human VEGF-specific oligonucleotides Human VEGF-specific oligonucleotides

1995-03-02

1997-06-17

Rories, Charles C. P.

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

536 235, 536 243, 536 2431, 536 2433, 435 6, C07H 2100, A61K 3170, C12Q 168, C12N 510

Patent

active

056398727

ABSTRACT:
Disclosed are methods of reducing neovascularization and of treating various disorders associated with neovascularization. These methods include administering to a tissue or subject a synthetic oligonucleotide specific for vascular endothelial growth factor nucleic acid effective in inhibiting the expression of vascular endothelial growth factor.

REFERENCES:
patent: 5219739 (1993-06-01), Tischer et al.
patent: 5225326 (1993-07-01), Bresser et al.
patent: 5271941 (1993-12-01), Cho-Chung
E. Uhlmann et al. Chem. Rev. 90(4) (Jun. 1990) 543-84.
W. James Antiviral Chemistry & Chemotherapy 2(4) ('91) 191-214.
J. Holz et al. Mol. Cell. Biol. 8(2) (Feb. 1988) 963-73.
D. Tidd Anticancer Res. 10 ('90) 1169-82.
M. Cooney et al. Science 241 (Jul. 22, 1988) 456-9.
J. Milligan et al. J. Med. Chem. 36(14) (Jul. 9, 1993) 1923-37.
C. Stein et al. Science 261 (Aug. 20, 1993) 1004-12.
B. Tseng et al. Cancer Gene Therapy 1(1) (Mar. 1994) 65-71.
P. Westermann et al. Biomed. Bichim. Acta 48(1) ('89) 85-93.
J. Wetmur Cric. Rev. Biochem. Mol. Biol. 26 (3/4) ('91) 227-59.
Pierce et al. (1995) Investigative Ophthalmology & Visual Science 36:Abstract 3990.
Smith et al. (1995) Investigative Ophthalmology & Visual Science 36:Abstract 3992.
Uchida et al., (1995) Antisense Res. & Dev. 5(1):87 (Abstract OP-10).
Nomura et al., (1995) Antisense Res. & Dev. 5(1):91 (Abstract OP-18).
Michaelson (1948) Trans. Ophthalmol. Soc. U. K. 68:137-180.
Ashton et al. (1954) Br. J. Ophthalmol. 38:397-432.
Am. J. Ophthalmol. (1976) 81:383-396.
Senger et al. (1986) Cancer Res. 46:5629-5632.
Folkman et al. (1987) Science 235:442-446.
Ophthalmol. (1991) 98:741-840 (Supplement).
Klagsbrun et al. (1991) Ann. Rev. Physiol. 53:217-239.
Tischer et al. (1991) J. Biol. Chem. 266:11947-11954.
Claffey et al. (1992) J. Biol. Chem. 267:16317-16322.
Plate et al. (1992) Nature 359:845-848.
Plouet et al. (1992) Invest. Ophthalmol. Vis. Sci. 34:900.
Schweiki et al. (1992) Nature 359:843-845.
Adamis et al. (1993) Biochem. Biophys. Res. Commun. 193:631-638.
Adamis et al. (1993) Invest. Ophthalmol. Vis. Sci. 34:1440.
Kim et al. (1993) Nature 362:841-844.
Knighton et al. (1983) Science 221:1283-1285.
Miller et al. (1993) Principles and Practice of Ophthalmology, W.B. Saunders, Philadelphia, pp. 760.
Aiello et al. (1994) New Eng. J. Med. 331:1480-1487.
Aiello et al. (1994) Invest. Ophthalmol. Vis. Sci. 35:1868.
Bressler et al., Principles and Practices of Ophthalmology (eds. Albert and Jakobiac), W.B. Saunders Co., Philadelphia, PA) (1994) vol. 2.
Foster in Harrison's Principles of Internal Medicine (Isselbacher et al., eds.) McGraw-Hill, Inc., New York (1994) pp. 1994-1995.
Pierce et al. (1994) Int. Ophth. Clinics 34:121-148.
Simorre-Pinatel et al. (1994) Invest. Ophthalmol. Vis. Sci. 35:3393-3400.
Smith et al. (1994) Invest. Ophthalmol. Vis. Sci. 35:1442.
Smith et al. (1994) Invest. Ophthalmol. Vis. Sci. 35:101-111.
Focus (Jan. 6, 1995).
Ophthalmology World News (1995) p. 26.
Ophthalmology Times (Jan. 16-22, 1995).
Pierce et al. (1995) Proc. Natl. Acad. Sci. (USA) 92 (Jan. '95) 905-9.
Monacci et al. (1993) American Journal Of Physiology 264:c995-c1002.
Garrido et al. (1993) Growth Factors 8:109-117.

Affiliated with

Also associated with

Rating

Human VEGF-specific oligonucleotides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Human VEGF-specific oligonucleotides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human VEGF-specific oligonucleotides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2158839